financetom
Business
financetom
/
Business
/
United Breweries posts over 2-fold rise in Q4 profit at Rs 97.53 crore
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
United Breweries posts over 2-fold rise in Q4 profit at Rs 97.53 crore
Apr 28, 2021 7:10 AM

Beer maker United Breweries Ltd on Tuesday reported an over two-fold jump in consolidated net profit at Rs 97.53 crore in the fourth quarter ended March 31, riding on good volume growth in markets across the country. The company had posted a consolidated net profit of Rs 41.82 crore in the year-ago quarter, United Breweries Ltd (UBL) said in a regulatory filing.

Consolidated total income from operations stood at Rs 3,629.75 crore as against Rs 3,100.67 crore in the same quarter previous fiscal, it added. ”All markets across the country witnessed good volume growth in Q4 barring a few key markets like Telangana, Orissa, and Delhi resulting in an overall 9 percent growth,” UBL said.

The quarter witnessed double-digit growth in all regions barring the South, which recorded low single-digit growth because of the sharp decline in Telangana due to covid excise taxation, it said adding the quarter also witnessed good recovery in key markets like Karnataka, Maharashtra and Goa.

In the north, the company said states like Rajasthan, Punjab, Haryana and Himachal Pradesh recorded good growth except Delhi with UP remaining flat, while in the east, West Bengal witnessed over 100 percent growth even as other markets grew at double digits barring Orissa.

For the fiscal ended March 31, the company posted a consolidated net profit of Rs 113.83 crore as compared to Rs 428.29 crore, down 73 per cent. The company said its consolidated total income from operations in FY21 was down at Rs 10,236.01 crore from Rs 14,660.45 crore in FY20.

”It has been an exceptional year with lockdowns, prolonged trade closures and Covid related duty increases. As a result, volumes for full-year were down by 39 percent. Demand and underlying profitability saw strong sequential recovery quarter by quarter,” UBL said. The company said it continues to focus on health and safety for its employees and stakeholders during this second wave of the pandemic.

”Due to the second wave, the industry outlook is volatile. The impact will depend on the magnitude and duration of lockdowns, including any partial or full trade restrictions. UBL has and will continue to manage all elements of costs and capital investments with agility in light of the uncertain demand given the situation of the second COVID-19 wave across the country,” it added.

On the outlook, the company said it has observed recovery of underlying consumer demand post the first COVID-19 wave and continues to be optimistic about the long-term growth drivers of the industry.

First Published:Apr 28, 2021 4:10 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Next Boeing CEO should understand past mistakes, airlines boss says
Next Boeing CEO should understand past mistakes, airlines boss says
Jun 2, 2024
DUBAI, June 2 (Reuters) - The next Boeing ( BA ) CEO should have an understanding of what led up to its current crisis and be prepared to look outside for examples of best industrial practices, the head of the International Air Transport Association said on Sunday. It is not for me to say who should be running Boeing (...
OPEC+ agrees to extend voluntary output cuts into Q3'24, talks continue, sources say
OPEC+ agrees to extend voluntary output cuts into Q3'24, talks continue, sources say
Jun 2, 2024
LONDON (Reuters) - OPEC+ has agrees to extend voluntary oil production cuts of 2.2 million barrels per day into the third quarter of 2024, two OPEC+ sources said on Sunday. Talks about cuts for the fourth quarter and 2025 continue, the sources said. (Reporting by OPEC Newsroom; Editing by Emelia Sithole-Matarise) ...
GSK blood cancer drug nearly halves risk of death in late-stage trial
GSK blood cancer drug nearly halves risk of death in late-stage trial
Jun 2, 2024
June 2 (Reuters) - GSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage study presented at a medical meeting on Sunday. In the trial of 302 patients with relapsed or difficult-to-treat multiple myeloma, 71% of those who received Blenrep in...
Pre-surgery treatment with Bristol Myers combination therapy  leads to better skin cancer outcomes
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes
Jun 2, 2024
June 2 (Reuters) - Treatment with Bristol Myers Squibb's ( BMY ) immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer had spread to lymph nodes had better outcomes than those who did not get the drugs before node removal procedures, according to data from a late-stage trial released on Sunday. The study of 423 patients with...
Copyright 2023-2025 - www.financetom.com All Rights Reserved